Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XIENCE V Everolimus Eluting Coronary Stent System India Post-marketing Single-Arm Study

Trial Profile

XIENCE V Everolimus Eluting Coronary Stent System India Post-marketing Single-Arm Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms XIENCE-V-India
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 18 Mar 2019 Results of a pooled analysis of the four XIENCE Post-Approval Trials assessing the impact of Renal Function in Patients With High Bleeding Risk Who Underwent Percutaneous Coronary Intervention With XIENCE, presented at the 68th Annual Scientific Session of the American College of Cardiology
    • 25 Sep 2018 Results of a pooled analysis from XIENCEV USA, XIENCEV Japan, XIENCE V China and XIENCE V India trials presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 25 Sep 2018 Results of a pooled analysis from post-approval registries XIENCE V USA, XIENCE V Japan, and XIENCE V India (n=8020) presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top